文献速递免疫规划

既往完成新冠mRNA疫苗基础免疫的健康日本成人接种第二剂异源加强针NVX-CoV2373(TAK-019)的免疫原性与安全性:3期开放标签试验中期分析报告

Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
PubMed 文献 · Vaccine · 2023-12-21

3期单臂开放标签TAK-019-3001研究评估健康日本成人间隔5个月接种两剂异源NVX-CoV2373加强针,受试者此前已完成新冠mRNA疫苗基础免疫6-12个月。中期分析纳入129例接种第二剂加强针者,ED15抗SARS-CoV-2 rS血清IgG和针对祖先株的血清中和抗体滴度分别为第一剂加强后5个月(ED1)的4.0倍和3.0倍,分别为第一剂加强后14天(第15天)的3.0倍和1.4倍;第二剂加强后7天内征集性局部和全身不良事件发生率分别为73.6%和51.2%,多为2级或以下。

要点

  • 第二剂异源NVX-CoV2373加强针诱导的抗SARS-CoV-2免疫应答比第一剂加强针更强。
  • 第二剂加强后7天内征集性局部和全身不良事件发生率分别为73.6%和51.2%,多为2级或以下。
  • 第二剂加强后28天内7%受试者发生非征集性不良事件,均与治疗无关;无死亡或导致退出研究的不良事件。

核心结论

  • 健康日本成人接种第二剂异源NVX-CoV2373加强针诱导的抗SARS-CoV-2免疫应答比第一剂加强针更强,且耐受性良好,未发现新的安全性问题。

研究设计与样本

  • 3期、单臂、开放标签TAK-019-3001研究,评估健康日本成人间隔5个月接种两剂异源NVX-CoV2373加强针,受试者此前已完成新冠mRNA疫苗基础免疫6-12个月。
  • 本中期分析评估研究扩展部分第二剂加强针的免疫原性和安全性,并与第一剂加强针比较;免疫原性在扩展第1天(ED1,接种前)和ED15评估。
  • 150例受试者接种第一剂NVX-CoV2373加强针,其中129例在ED1接种第二剂加强针;评估接种后7天内征集性和28天内非征集性不良事件。

主要发现

  • ED15抗SARS-CoV-2 rS血清免疫球蛋白G滴度为第一剂加强后5个月(ED1)的4.0倍,ED15血清中和抗体滴度为ED1的3.0倍。
  • ED15抗SARS-CoV-2 rS血清免疫球蛋白G滴度为第一剂加强后14天(第15天)的3.0倍,ED15血清中和抗体滴度为第15天的1.4倍。
  • 第二剂加强后7天内征集性局部不良事件发生率为73.6%,征集性全身不良事件发生率为51.2%,多为2级或以下。
  • 第二剂加强后28天内7%的受试者发生非征集性不良事件,均与治疗无关;无死亡或导致研究退出的事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3, single-arm, open-label TAK-019-3001 study assessed two heterologous booster doses of NVX-CoV2373 administered 5 months apart in healthy Japanese adults who had completed a primary series of a COVID-19 mRNA vaccine 6-12 months previously. In the main part of this study, a first booster induced rapid and robust anti-SARS-CoV-2 immune responses, addressing waning immunity in participants. METHODS: This interim analysis evaluated the immunogenicity and safety of a second booster in the extension part of this study including comparisons with the first booster. Immunogenicity was assessed on extension day (ED) 1 (before vaccination) and ED15. Solicited and unsolicited adverse events occurring in the 7 and 28 days, respectively, after vaccination were assessed. RESULTS: Of the 150 participants who received a first NVX-CoV2373 booster, 129 were administered a second booster on ED1. Participant characteristics were consistent between the main and extension parts of the study. Titres of anti-SARS-CoV-2 rS serum immunoglobulin G and serum neutralizing antibodies against the SARS-CoV-2 ancestral strain at ED15 were 4.0- and 3.0-fold higher, respectively, than those observed 5 months after the first booster on ED1, and 3.0- and 1.4-fold higher, respectively, than those observed 14 days after the first booster on day 15. The proportions of participants who experienced solicited local and systemic adverse events (AEs) in the 7 days after the second booster were 73.6 % and 51.2 %, respectively: most were of grade 2 severity or lower. Seven percent of participants experienced unsolicited AEs in the 28 days after the second booster: all were unrelated to the treatment. There were no deaths or AEs leading to study discontinuation. DISCUSSION: A second heterologous NVX-CoV2373 booster in healthy Japanese adults induced more robust anti-SARS-CoV-2 immune responses than the first booster. The second booster was well tolerated. No new safety concerns were identified.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kuriyama K, Murakami K, Sugiura K, et al. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial. Vaccine. 2023. PMID: 38129286. doi:10.1016/j.vaccine.2023.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。